The landscape of cancer cell line metabolism.
Animals
Asparaginase
/ therapeutic use
Asparagine
/ metabolism
Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor
/ antagonists & inhibitors
Cell Line, Tumor
DNA Methylation
Female
Gene Knockdown Techniques
Humans
Kynurenine
/ metabolism
Liver Neoplasms
/ genetics
Metabolome
Mice
Mice, Nude
Neoplasms
/ genetics
Stomach Neoplasms
/ genetics
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
02
10
2018
accepted:
20
02
2019
entrez:
10
5
2019
pubmed:
10
5
2019
medline:
11
7
2019
Statut:
ppublish
Résumé
Despite considerable efforts to identify cancer metabolic alterations that might unveil druggable vulnerabilities, systematic characterizations of metabolism as it relates to functional genomic features and associated dependencies remain uncommon. To further understand the metabolic diversity of cancer, we profiled 225 metabolites in 928 cell lines from more than 20 cancer types in the Cancer Cell Line Encyclopedia (CCLE) using liquid chromatography-mass spectrometry (LC-MS). This resource enables unbiased association analysis linking the cancer metabolome to genetic alterations, epigenetic features and gene dependencies. Additionally, by screening barcoded cell lines, we demonstrated that aberrant ASNS hypermethylation sensitizes subsets of gastric and hepatic cancers to asparaginase therapy. Finally, our analysis revealed distinct synthesis and secretion patterns of kynurenine, an immune-suppressive metabolite, in model cancer cell lines. Together, these findings and related methodology provide comprehensive resources that will help clarify the landscape of cancer metabolism.
Identifiants
pubmed: 31068703
doi: 10.1038/s41591-019-0404-8
pii: 10.1038/s41591-019-0404-8
pmc: PMC6629041
mid: NIHMS1033364
doi:
Substances chimiques
Kynurenine
343-65-7
Asparagine
7006-34-0
Asparaginase
EC 3.5.1.1
Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor
EC 6.3.5.-
ASNS protein, human
EC 6.3.5.4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
850-860Subventions
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK040561
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176058
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA217848
Pays : United States
Références
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Science. 2012 May 25;336(6084):1040-4
pubmed: 22628656
Nat Biotechnol. 2016 Apr;34(4):419-23
pubmed: 26928769
Cell. 2017 Feb 9;168(4):657-669
pubmed: 28187287
Cancer Res. 2008 Mar 1;68(5):1303-9
pubmed: 18316592
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
Cancer Discov. 2014 Nov;4(11):1290-8
pubmed: 25182153
Cancer Cell. 2011 Jan 18;19(1):17-30
pubmed: 21251613
Nat Rev Cancer. 2010 Apr;10(4):267-77
pubmed: 20300106
Nat Med. 2003 Oct;9(10):1269-74
pubmed: 14502282
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Crit Rev Oncol Hematol. 2007 Mar;61(3):208-21
pubmed: 17011787
Trends Immunol. 2013 Mar;34(3):137-43
pubmed: 23103127
Clin Chem. 2013 Nov;59(11):1657-67
pubmed: 23897902
Cell. 2014 Jan 16;156(1-2):317-331
pubmed: 24439385
Nature. 2017 Feb 2;542(7639):119-123
pubmed: 28099419
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Nature. 2009 Dec 10;462(7274):739-44
pubmed: 19935646
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2040-5
pubmed: 14764894
Eur J Cancer. 2017 May;76:167-182
pubmed: 28324751
Elife. 2015 Oct 24;4:
pubmed: 26499495
Nat Rev Cancer. 2011 Feb;11(2):85-95
pubmed: 21258394
J Immunol. 2010 Sep 15;185(6):3190-8
pubmed: 20720200
Nature. 2018 Feb 15;554(7692):378-381
pubmed: 29414946
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Cell. 2017 Jul 27;170(3):577-592.e10
pubmed: 28753431
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Biochim Biophys Acta. 1991 Jun 18;1065(2):231-8
pubmed: 2059655